ARDS (Aridis Pharmaceuticals) Change In Receivables: $1.72 Mil (TTM As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARDS Aridis Pharmaceuticals Inc ARDS
12 GF Score
Price $0.00
View Full Analysis

What is Aridis Pharmaceuticals Change In Receivables?

Aridis Pharmaceuticals ARDS 12 Change In Receivables is $1.72 Mil as of Sep. 2023. GuruFocus rates ARDS with a GF Score™ of 12/100.

Aridis Pharmaceuticals's change in receivables for the quarter that ended in Sep. 2023 was $-0.30 Mil. It means Aridis Pharmaceuticals's Accounts Receivable increased by $0.30 Mil from Jun. 2023 to Sep. 2023 .

Aridis Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2022 was $-1.00 Mil. It means Aridis Pharmaceuticals's Accounts Receivable increased by $1.00 Mil from Dec. 2021 to Dec. 2022 .

Aridis Pharmaceuticals's Accounts Receivable for the quarter that ended in Sep. 2023 was $0.42 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Aridis Pharmaceuticals's liquidation value for the three months ended in Sep. 2023 was $-17.99 Mil.

Aridis Pharmaceuticals  (OTCPK:ARDS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Aridis Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.417/0*91
=

2. In Ben Graham's calculation of liquidation value, Aridis Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Aridis Pharmaceuticals's liquidation value for the quarter that ended in Sep. 2023 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.035-18.336+0.75 * 0.417+0.5 * 0
=-17.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aridis Pharmaceuticals Change In Receivables Related Terms

Aridis Pharmaceuticals Change In Receivables Historical Data

* Premium members only.

The historical data trend for Aridis Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aridis Pharmaceuticals Change In Receivables Chart

Aridis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Change In Receivables
Get a 7-Day Free Trial -1.66 0.11 -0.63 0.13 -1.00

Aridis Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.34 -0.99 1.14 1.86 -0.30
ARDS
12GF Score
Aridis Pharmaceuticals Inc ARDS
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aridis Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $1.72 Mil mean?
Aridis Pharmaceuticals (ARDS) has a Change In Receivables of $1.72 Mil as of Sep. 2023. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Aridis Pharmaceuticals and its competitors.
Is Aridis Pharmaceuticals' Change In Receivables too high?
Aridis Pharmaceuticals' current Change In Receivables is $1.72 Mil. Overall, Aridis Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Aridis Pharmaceuticals' Change In Receivables compare to ARTL and REVB?
Aridis Pharmaceuticals' Change In Receivables of $1.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Aridis Pharmaceuticals and its competitors. Aridis Pharmaceuticals's current Change In Receivables is $1.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aridis Pharmaceuticals stock overvalued right now?
Aridis Pharmaceuticals (ARDS) has a current Change In Receivables of $1.72 Mil. The current Change In Receivables is $1.72 Mil. Aridis Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Aridis Pharmaceuticals (ARDS), the current Change In Receivables is $1.72 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aridis Pharmaceuticals Business Description

Address 983 University Avenue, Building B, Los Gatos, CA, USA, 95032
Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.
12GF Score

Get the complete analysis for ARDS

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price